2 Under-the-Radar Biotech Stocks to Buy in 2023
With that said, let's consider two biotech stocks, neither of which is a household name, that could deliver solid returns over the next five years and more: Exelixis (NASDAQ: EXEL) and Sarepta Therapeutics (NASDAQ: SRPT). Oncology is one of the most fiercely competitive therapeutic areas in the biotech industry. Exelixis, a mid-cap biotech, is just a small player in the field.